Early Informed Patients With Lung Cancer Have Greater Survival Rates
Patients with lung cancer who are given the opportunity to be informed of their diagnosis have a longer median survival time.
Lung Cancer
Case Study: Typical Progression of COVID-19 in Metastatic Lung Adenocarcinoma
A case study of an older man with metastatic lung adenocarcinoma who presented with symptoms of COVID-19 demonstrated patients with cancer have a similar COVID-19 disease progression as the general population.
Brigatinib Approved as First-Line Treatment for ALK-Positive Metastatic NSCLC
The FDA has approved brigatinib as a first-line treatment of adults with anaplastic lymphoma kinase(ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Distinguishing ILD From COVID-19 in Patients Treated With EGFR-TKIs
Optimal treatment of patients with EGFR-TKI–associated ILD is based on rapid diagnosis and the timely implementation of specific interventions.
CHEST/AABIP Recommendations for Bronchoscopy During COVID-19 Pandemic
The COVID-19 pandemic has posited a significant risk to healthcare workers, particularly to those who perform bronchoscopy, among other open airway procedures.
Atezolizumab Gains Approval for Additional Lung Cancer Indication
The approval was based on data from the phase 3 IMpower110 study that compared the efficacy and safety of atezolizumab monotherapy to platinum-based chemotherapy in PD-L1-selected, chemotherapy-naive patients with stage IV NSCLC without ALK or EGFR mutations.
Nivolumab/Ipilimumab Approved for First-Line Treatment of Metastatic NSCLC
The FDA has approved the combination of Opdivo plus Yervoy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
Lower Calculated Lung Cancer Risk in Black Patients Eligible for Screening
Compared with white patients, black patients with screen-detected cancers had a lower calculated lung cancer risk, despite having a significantly higher mean 6-year lung cancer risk.
Selpercatinib Gets Accelerated Approval for RET-Driven Lung, Thyroid Cancers
The FDA has granted accelerated approval to selpercatinib for the treatment of metastatic RET fusion-positive NSCLC, RET fusion-positive thyroid cancer, and RET-mutant MTC.
A Call to Investigate IL-17 as Drug Target for Lung Cancer, COVID-19
Interleukin 17 may be a therapeutic target worth investigating for patients with lung cancer and SARS-CoV-2 infection, existing literature suggests.
-
Loading...
-
Loading...
Next post in Lung Infection
